Key insight: A letter in Nature Methods noting flaws in the CRISPR gene editing system spooked investors today, but it shouldn’t have — because we’ve long known about those problems.

A letter in Nature Methods pointing out potentially dangerous flaws in the CRISPR-Cas9 genome editing system gave biotech investors a sinking feeling on Tuesday, and stocks in genome-editing companies had the same experience. By the close of trading Editas Medicine had fallen nearly 12 percent, Crispr Therapeutics was down more than 5 percent, and Intellia Therapeutics had plunged just over 14 percent.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X